How Does Stelara Work?
Stelara (ustekinumab) is a monoclonal antibody that targets and blocks interleukin-12 (IL-12) and interleukin-23 (IL-23). These cytokines drive inflammation in autoimmune diseases like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis by activating T-helper cells (Th1 and Th17 pathways). By binding to the shared p40 subunit of IL-12 and IL-23, Stelara prevents their interaction with the IL-12 receptor on immune cells, reducing pro-inflammatory signaling and cytokine production.[1][2]
What Conditions Does It Treat?
Approved for plaque psoriasis (moderate-to-severe), psoriatic arthritis, Crohn's disease (moderate-to-severe), and ulcerative colitis. It interrupts the IL-12/23 axis central to these Th1/Th17-mediated disorders, leading to decreased skin plaques, joint inflammation, and gut damage.[1][3]
How Is It Different from Other Biologics?
Unlike TNF inhibitors (e.g., Humira, which block tumor necrosis factor), Stelara specifically inhibits IL-12/IL-23 without broad immunosuppression. It contrasts with IL-17 inhibitors (e.g., Cosentyx) or IL-23-specific drugs (e.g., Tremfya, which targets only the p19 subunit of IL-23). This selectivity lowers some infection risks while targeting psoriasis/Crohn's pathways.[2][4]
Dosing and Administration Basics
Subcutaneous injection: 45 mg or 90 mg based on weight for psoriasis/psoriatic arthritis; induction doses for IBD followed by maintenance. Acts within weeks for skin symptoms, longer for gut response.[1]
Common Side Effects and Risks
Upper respiratory infections, headache, injection-site reactions. Increased risk of serious infections, malignancies, or hypersensitivity; monitor for tuberculosis reactivation. Not for active infections.[1][3]
Patent Status and Biosimilars
Janssen (Johnson & Johnson) holds patents on ustekinumab; key U.S. composition-of-matter patent expires around 2023-2025, but formulation/method patents extend protection to 2032+. Challenges from Amgen, Samsung Bioepis, and others aim for earlier biosimilar entry. Check DrugPatentWatch.com for latest expiry dates and litigation.[5]
[1]: FDA Stelara Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761044s022lbl.pdf
[2]: Stelara Prescribing Information - https://www.stelara.com/
[3]: Crohn's & Colitis Foundation - https://www.crohnscolitisfoundation.org/medication/ustekinumab-stelara
[4]: New England Journal of Medicine Review on IL-23 Inhibitors - https://www.nejm.org/doi/full/10.1056/NEJMra1901199
[5]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/STELARA